Histamine H3 Antagonist Combination for Psychotropic Side Effects
Solution Overview
Problem
Second-generation antipsychotics and certain antidepressants often cause excessive weight gain and sedation, leading to distressing side effects, reduced treatment efficacy, and increased risks of type 2 diabetes, cardiovascular disorders, and cancer, with existing combination therapies not being sufficiently effective.
Innovation Solution
A new medicament combining an antipsychotic or antidepressant with a histamine H3 receptor antagonist or inverse agonist, such as an imidazole derivative, to limit weight gain, sedation, and enhance procognitive effects, while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If second-generation antipsychotics or certain antidepressants are administered chronically, then therapeutic effects are achieved, but excessive weight gain occurs
Solution Approach 1:
The patent introduces a histamine H3 receptor antagonist or inverse agonist as an intermediary substance that mediates between the antipsychotic/antidepressant treatment and the harmful weight gain effect. This third substance selectively blocks the H3 receptor pathway responsible for weight gain without interfering with the therapeutic mechanism of the primary psychotropic agent, thus resolving the contradiction between maintaining therapeutic efficacy and preventing harmful side effects.
Solution Approach 2:
The invention extracts and isolates the specific H3 receptor pathway that mediates weight gain from the overall pharmacological action of psychotropic drugs. By using selective H3 receptor antagonists, the harmful weight gain effect is separated from the beneficial therapeutic effects, allowing the latter to be maintained while the former is specifically blocked through targeted intervention at the H3 receptor level.
2Reliability
If second-generation antipsychotics are administered, then antipsychotic effect is achieved, but sedation occurs
Solution Approach 1:
The histamine H3 receptor antagonist serves as an intermediary that specifically counteracts the sedative effect mediated by H3 receptor activation without blocking the antipsychotic mechanism. By selectively antagonizing H3 receptors, the patent eliminates the unwanted sedation while preserving the therapeutic antipsychotic action through a dedicated intermediary substance.
Solution Approach 2:
The invention applies local quality by targeting the specific H3 receptor pathway that mediates sedation, rather than broadly blocking all histaminergic or other receptors. The selective H3 receptor antagonist acts locally on the sedative pathway, differentiating it from other pharmacological pathways, thereby eliminating sedation while maintaining antipsychotic efficacy through pathway-specific intervention.
3Reliability
If higher doses of antipsychotics are administered to improve efficacy, then therapeutic effect increases, but weight gain and sedation increase
Solution Approach 1:
The H3 receptor antagonist acts as a protective intermediary that allows higher doses of antipsychotics to be administered without proportionally increasing harmful effects. By blocking the H3 receptor pathway, the intermediary substance decouples the relationship between dose escalation and side effect escalation, enabling dose optimization for maximum therapeutic benefit while the antagonist prevents the parallel increase in weight gain and sedation.
Solution Approach 2:
The patent applies partial action by using the H3 receptor antagonist to specifically counteract only the harmful portions of the drug's effect (weight gain and sedation) while allowing the therapeutic portions to proceed unchecked. This selective partial blocking enables the system to tolerate higher antipsychotic doses for enhanced therapeutic effect without suffering proportional increases in adverse effects.
4Object-generated harmful factors
If existing combination therapies (fluoxetine, sibutramine, amantadine, tamoxifen) are used to prevent weight gain, then some weight control is achieved, but they are not sufficiently convincing for therapeutic application
Solution Approach 1:
The patent fundamentally changes the parameter of receptor selectivity by moving from non-specific or multi-receptor combination therapies to highly selective H3 receptor antagonism. This parameter change in mechanism of action provides a more convincing and rational therapeutic basis, as the selective H3 blockade directly targets the known pathway mediating weight gain without the off-target effects and therapeutic uncertainties of previous combination approaches.
Data Source
AI summary
Medicament comprising, in a pharmaceutically acceptable vehicle, an anti-psychotic or an antidepressant (A), which, on its own, has an undesirable effect of a gain in body weight or sedation, and an antagonist and/or inverse agonist (B) of the histamine H3 receptor, the antagonist and/or inverse agonist of the histamine H3 receptor being present in a therapeutically effective amount for ensuring at least one of the following three effects: suppression or at least limitation of the undesirable effect of weight gain, suppression or limitation of the undesirable effect on alertness, epilepsy/convulsions, increase in the precognitive effect of the treatment. Use of such an antagonist or inverse agonist for the preparation of a medicament which is to ensure at least one of the said three effects in a patient treated by such an antipsychotic or antidepressant.



